Le, X., Spira, A. I., Johnson, M. L., Nagasaka, M., Philipovskiy, A., Patel, J. D., Gordon, S. W., Riess, J. W., Bazhenova, L., Puri, S., Horinouchi, H., Izumi, H., Li, M. S., John, T., Parakh, S., Graber, A., Oxnard, G., Cui, J. J., Zhang, P., Yang, J. C. (2025). A phase 1/2 open-label, multicenter, first-in-human study of the safety, tolerability, pharmacokinetics, and antitumor activity of BH-30643 in adult subjects with locally advanced or metastatic NSCLC harboring EGFR and/or HER2 mutations (SOLARA).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps8663